Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nicardipine + sodium nitroprusside is a combination of two intravenous antihypertensive agents used for the rapid control of severe hypertension, particularly in critical care and perioperative settings. Nicardipine is a dihydropyridine calcium channel blocker that inhibits the influx of extracellular calcium into vascular smooth muscle and myocardium, leading to vasodilation and decreased systemic vascular resistance. Sodium nitroprusside (Nipride) is a direct-acting vasodilator that releases nitric oxide to relax both arteriolar and venous smooth muscle, resulting in rapid reduction of blood pressure. This combination may be considered when monotherapy with either agent does not achieve adequate blood pressure control or when tailored hemodynamic effects are desired. Both drugs act via different mechanisms but share the goal of prompt blood pressure reduction; their use requires close monitoring due to potential side effects such as hypotension or cyanide toxicity (with prolonged nitroprusside use).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nicardipine + sodium nitroprusside.